A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

• Status: Terminated
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept

Criteria

Inclusion

• relapsing-remitting MS

• at least 1 exacerbation in preceding 2 years

• at least 1 MRI lesion

• stable for 2 months prior to dosing

Exclusion

• progressive MS

• currently treated with an immunomodulatory therapy

• previously treated with an approved MS drug where treatment was discontinued for lack of efficacy

• active bacterial or viral infections